Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Monday a definitive agreement to acquire CymaBay Therapeutics Inc (Nasdaq:CBAY), a clinical-stage biopharmaceutical company with a focus on liver and other chronic diseases that have high unmet medical need.
Under the terms of the agreement Gilead will acquire CymaBay for USD32.50 per share in cash, amounting to a total equity value of USD4.3bn.
This acquisition marks Gilead's expansion in the liver disease space, bolstering its portfolio with CymaBay's investigational lead product candidate, seladelpar, which is designed for treating primary biliary cholangitis (PBC), including pruritus.
PBC is a rare, chronic liver disease predominantly affecting women, with symptoms such as pruritus and fatigue significantly impacting patients' quality of life. Seladelpar, an oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist, has demonstrated promising efficacy in regulating critical metabolic and liver disease pathways, earning FDA priority review status with approval anticipated in the third quarter of 2024.
The pivotal Phase 3 RESPONSE trial demonstrated seladelpar's superiority over placebo in achieving primary composite endpoints, including biochemical response and normalisation of alkaline phosphatase levels.
The transaction, approved by both companies' boards of directors, is expected to close in the first quarter of 2024, subject to regulatory approvals and customary closing conditions.
Akura Medical's application for trial of Katana Thrombectomy System receives US FDA approval
FDA accepts Ionis Pharmaceuticals' donidalorsen New Drug Application
Kazia Therapeutics secures FDA meeting to explore paxalisib pathways for glioblastoma
Boston Scientific to acquire Cortex Inc in strategic expansion of electrophysiology portfolio
Formosa Pharmaceuticals signs licensing agreement with DÁVI Farmaceutica
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
Eisai completes rolling BLA submission for lecanemab-irmb to FDA
Satsuma Pharmaceuticals and Shin Nippon Biomedical resubmit STS101 NDA to FDA
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
Sobi to present emapalumab data for treating macrophage activation syndrome at ACR Conference
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI